Biocon receives EIR with VAI classification for its Malaysian insulin manufacturing facility

Biocon announced that its subsidiary, Biocon Sdn Bhd has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) of its Insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between 10 February and 21 February 2020.

The Inspection has been closed with a 'VAI' (Voluntary Action Indicated) classification in the EIR, for the three observations issued at the conclusion of the inspection in Febraury 2020.

Powered by Capital Market - Live News